Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for KALA BIO, Inc. (KALA : NSDQ)

• Company Description    KALA BIO is a clinical-stage biopharmaceutical company. It focused on the research, development and commercialization of therapies for rare and severe diseases of the eye. The company' s lead product candidate consists KPI-012. KALA BIO, formerly known as Kala Pharmaceuticals Inc., is based in ARLINGTON, Mass. Number of Employees: 38

• Price / Volume Information    Yesterday's Closing Price: $17.00 Daily Weekly Monthly 20 Day Moving Average: 239,104 shares Shares Outstanding: 7.02 (millions) Market Capitalization: $119.36 (millions) Beta: -1.81 52 Week High: $18.89 52 Week Low: $2.92 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 110.66% 106.85% 12 Week 300.94% 264.02% Year To Date 144.96% 118.71%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1167 MASSACHUSETTS AVENUE - ARLINGTON,MA 02476 USA ph: 781-996-5252 fax: 781-642-0399 taylor.steiner@precisionaq.com http://www.kalarx.com

• General Corporate Information    Officers Mark Iwicki - Chairman Todd Bazemore - Chief Operating Officer and President Mary Reumuth - Chief Financial Officer; Treasurer and Secretary Marjan Farid - Director Andrew I. Koven - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 483119202 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/11/25 Share - Related Items Shares Outstanding: 7.02 Most Recent Split Date: 10.00 (0.02:1) Beta: -1.81 Market Capitalization: $119.36 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.22 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-5.23 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/11/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 45.89% vs. Previous Quarter: -21.28% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - -686.43 03/31/25 - -369.29 12/31/24 - -389.30 ROA 06/30/25 - -76.81 03/31/25 - -64.99 12/31/24 - -68.71 Current Ratio 06/30/25 - 2.10 03/31/25 - 1.99 12/31/24 - 3.11 Quick Ratio 06/30/25 - 2.10 03/31/25 - 1.99 12/31/24 - 3.11 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - -0.50 03/31/25 - 0.88 12/31/24 - 2.02 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 3.19 12/31/24 - 2.01 Debt-to-Capital 06/30/25 - - 03/31/25 - 76.16 12/31/24 - 66.75

Powered by Zacks Investment Research ©